[Body plethysmographic investigations with the new bronchodilator NAB365 (author's transl)].

NAB 365, a new beta2-adrenergic bronchodilator was tested in oral doses of 0,01, 0,02, 0,03, and 0,04 mg. An acute trial was carried out in outpatients, suffering from chronic obstructive airways disease. with doses of 0,02 and 0,04 mg NAB 365 a quick, dose related and statistically significant bronchodilation without remarkable side effects was found.